Hosted on MSN1mon
FDA approves Qelbree label update for ADHD treatmentThe new information in Section 12.2 of the label details Qelbree's partial agonist activity at the serotonin 5-HT2C receptor and its inhibition of the norepinephrine transporter. This multimodal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback